Page results
-
Acute Myeloid Leukaemia (AML) is a form of cancer that develops in your bone marrow and affects your blood cells.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
Your acute myeloid leukaemia (AML) treatment will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Acute lymphoblastic leukaemia (ALL) is a form of cancer that affects the cells in the bone marrow, the soft material inside your bones.
-
Your treatment for acute lymphoblastic leukaemia (ALL) will be delivered within a number of comprehensive specialised services led by medical and nursing cancer care experts.
-
Bed availability is a “significant” factor in determining whether or not a patient is admitted to a critical care bed after surgery, questioning whether some are getting the care they need, a new study from researchers at UCL and UCLH has found for the first time.
-
This page offers advice to patients who are feeling sick.
-
This page has been written by the Department of Neuroradiology at the National Hospital for Neurology and Neurosurgery (NHNN). Our aim is to provide you with information about endovascular treatments…
-
“No one is invulnerable” – stark messages from patients and staff about the realities of coronavirus
The enormous pressure our staff are under was the focus of a powerful BBC News report about the surge in Covid-19 cases broadcast on Wednesday 6 January.
File results
-
FOI/2022/0278 - Surgical tables in use at Trust
-
FOI/2022/0280 - Applications or tools to communicate digitally with patients
-
FOI/2022/0282 - Decontamination and infection control leads; risk assessment group meetings
-
FOI/2022/0283 - Enhanced disinfection methods to eliminate HAIs in theatres, clinical areas and wards
-
FOI/2022/0285 - Paediatric audiology
-
FOI/2022/0286 - Fat-shaming complaints
-
FOI/2022/0287 - Device related delays in delivery of medication/ enteral feeding
-
FOI/2022/0288 - Patient deaths awaiting discharge as inpatient
-
FOI/2022/0293 - Patients treated with Ponvory, Tysabri, Vumerity, Zeposia
-
FOI/2022/0294 - IT systems validation document management system